Azenta Inc AZTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZTA is a good fit for your portfolio.
News
-
Azenta Announces Fiscal 2024 Third Quarter Earnings Conference Call and Webcast
-
FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study
-
Azenta Announces Collaboration with the Crohn's & Colitis Foundation to Support its Crohn's Disease and Ulcerative Colitis Clinical Research
-
Azenta to Participate in the Jefferies Global Healthcare Conference
-
Azenta Opens the Doors to Its New Genomics Laboratory in Oxford, UK
-
Azenta Announces CEO Succession Plan
-
Azenta Reports Second Quarter Results for Fiscal 2024, Ended March 31, 2024
-
Azenta Announces Fiscal 2024 Second Quarter Earnings Conference Call and Webcast
Trading Information
- Previous Close Price
- $59.12
- Day Range
- $59.70–61.53
- 52-Week Range
- $44.00–69.16
- Bid/Ask
- $58.12 / $62.41
- Market Cap
- $3.25 Bil
- Volume/Avg
- 292,194 / 511,366
Key Statistics
- Price/Earnings (Normalized)
- 128.15
- Price/Sales
- 5.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 16.18%
Company Profile
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has two reportable segments that are Life Sciences Products and Life Sciences Services. It generates a substantial part of its revenue from its Life Sciences Services segment.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Growth
- Total Number of Employees
- 3,500
- Website
- https://www.azenta.com
Competitors
Valuation
|
Metric
|
AZTA
|
HPQ
|
6762
|
|---|---|---|---|
Price/Earnings (Normalized) | 128.15 | 10.72 | 29.56 |
Price/Book Value | 1.48 | — | 2.13 |
Price/Sales | 5.44 | 0.69 | 1.73 |
Price/Cash Flow | 67.15 | 8.56 | 11.17 |
Price/Earnings
AZTA
HPQ
6762
Financial Strength
|
Metric
|
AZTA
|
HPQ
|
6762
|
|---|---|---|---|
Quick Ratio | 4.81 | 0.38 | 1.24 |
Current Ratio | 5.86 | 0.75 | 1.70 |
Interest Coverage | — | 6.93 | 5.74 |
Quick Ratio
AZTA
HPQ
6762
Profitability
|
Metric
|
AZTA
|
HPQ
|
6762
|
|---|---|---|---|
Return on Assets (Normalized) | −0.57% | 9.22% | 4.00% |
Return on Equity (Normalized) | −0.65% | — | 8.35% |
Return on Invested Capital (Normalized) | −2.14% | 41.27% | 5.50% |
Return on Assets
AZTA
HPQ
6762
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| Nqfwlqvphw | Drjw | $156.8 Bil | |||
| Becton Dickinson & Co
BDX
| Qtrlvchs | Fzjgpph | $68.6 Bil | |||
| Alcon Inc
ALC
| Xyzrltgly | Rsrfxvy | $46.5 Bil | |||
| Coloplast A/S ADR
CLPBY
| Snpryqcbs | Cbsm | $29.1 Bil | |||
| ResMed Inc
RMD
| Xydzjwgyj | Wbjmjf | $28.9 Bil | |||
| West Pharmaceutical Services Inc
WST
| Fdkbtdhk | Bjps | $20.7 Bil | |||
| The Cooper Companies Inc
COO
| Phjynghlm | Swxbsm | $18.6 Bil | |||
| Hologic Inc
HOLX
| Fhxmptm | Wwhhjgc | $18.4 Bil | |||
| Baxter International Inc
BAX
| Yzrbdmrz | Sgslc | $18.1 Bil | |||
| Teleflex Inc
TFX
| Xpgj | Qqlz | $10.4 Bil |